Gypenoside XVII regulates apoptosis and fear extinction deficits mediated by post-traumatic stress disorder through the PERK/CHOP signaling pathway

GP-17 demonstrates therapeutic potential for PTSD by modulating fear and anxiety in SPS rats through the PERK/CHOP pathway, positioning it as a promising candidate for PTSD treatment via the endoplasmic reticulum stress pathway.